Daghlas, I;
Karhunen, V;
Ray, D;
Zuber, V;
Burgess, S;
Tsao, PS;
Lynch, JA;
Lee, KM;
Voight, BF;
Chang, K-M;
et al.
Daghlas, I; Karhunen, V; Ray, D; Zuber, V; Burgess, S; Tsao, PS; Lynch, JA; Lee, KM; Voight, BF; Chang, K-M; Baker, EH; Damrauer, SM; Howson, JMM; Vujkovic, M; Gill, D
(2021)
Genetic Evidence for Repurposing of GLP1R (Glucagon-Like Peptide-1 Receptor) Agonists to Prevent Heart Failure.
J Am Heart Assoc, 10 (13).
e020331.
ISSN 2047-9980
https://doi.org/10.1161/JAHA.120.020331
SGUL Authors: Gill, Dipender Preet Singh Baker, Emma Harriet
|
PDF
Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
|
![]() |
Microsoft Word (.docx)
Accepted Version
Available under License Creative Commons Attribution. Download (343kB) |
Abstract
Background This study was designed to investigate the genetic evidence for repurposing of GLP1R (glucagon-like peptide-1 receptor) agonists to prevent heart failure (HF) and whether the potential benefit exceeds the benefit conferred by more general glycemic control. Methods and Results We applied 2-sample Mendelian randomization of genetically proxied GLP1R agonism on HF as the main outcome and left ventricular ejection fraction as the secondary outcome. The associations were compared with those of general glycemic control on the same outcomes. Genetic associations were obtained from genome-wide association study summary statistics of type 2 diabetes mellitus (228 499 cases and 1 178 783 controls), glycated hemoglobin (n=344 182), HF (47,309 cases and 930 014 controls), and left ventricular ejection fraction (n=16 923). Genetic proxies for GLP1R agonism associated with reduced risk of HF (odds ratio per 1 mmol/mol decrease in glycated hemoglobin 0.75; 95% CI, 0.64-0.87; P=1.69×10-4), and higher left ventricular ejection fraction (SD change in left ventricular ejection fraction per 1 mmol/mol decrease in glycated hemoglobin 0.22%; 95% CI, 0.03-0.42; P=0.03). The magnitude of these benefits exceeded those expected from improved glycemic control more generally. The results were similar in sensitivity analyses, and we did not find evidence to suggest that these associations were mediated by reduced coronary artery disease risk. Conclusions This genetic evidence supports the repurposing of GLP1R agonists for preventing HF.
Item Type: | Article | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Additional Information: | Copyright © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. | ||||||||||||||||||||||||
Keywords: | GLP1R, Mendelian randomization, diabetes mellitus, ejection fraction, heart failure | ||||||||||||||||||||||||
SGUL Research Institute / Research Centre: | Academic Structure > Infection and Immunity Research Institute (INII) | ||||||||||||||||||||||||
Journal or Publication Title: | J Am Heart Assoc | ||||||||||||||||||||||||
ISSN: | 2047-9980 | ||||||||||||||||||||||||
Language: | eng | ||||||||||||||||||||||||
Dates: |
|
||||||||||||||||||||||||
Publisher License: | Creative Commons: Attribution 4.0 | ||||||||||||||||||||||||
Projects: |
|
||||||||||||||||||||||||
PubMed ID: | 34184541 | ||||||||||||||||||||||||
Go to PubMed abstract | |||||||||||||||||||||||||
URI: | https://openaccess.sgul.ac.uk/id/eprint/113420 | ||||||||||||||||||||||||
Publisher's version: | https://doi.org/10.1161/JAHA.120.020331 |
Statistics
Actions (login required)
![]() |
Edit Item |